Search Result

Results for "

PF

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 5-HT Receptor (10) Acetyl-CoA Carboxylase (2) Acyltransferase (5) ADAMTS (1) ADC Antibody (1) ADC Payload (2) Adrenergic Receptor (4) Akt (1) Aminotransferases (Transaminases) (2) AMPK (5) Amyloid-β (4) Anaplastic lymphoma kinase (ALK) (12) Androgen Receptor (3) Antibiotic (11) Antibody-Drug Conjugates (ADCs) (4) Apoptosis (32) Arrestin (1) Aurora Kinase (4) Autophagy (20) Bacterial (13) Bcr-Abl (1) Beta-secretase (2) Biochemical Assay Reagents (4) Btk (5) c-Fms (1) c-Met/HGFR (11) c-Myc (1) Cadherin (1) Cannabinoid Receptor (2) Casein Kinase (4) Caspase (3) CCR (8) CD20 (1) CD22 (1) CD47 (1) CDK (6) Checkpoint Kinase (Chk) (1) CXCR (3) Cyclic GMP-AMP Synthase (1) Cytochrome P450 (4) Dihydroorotate Dehydrogenase (2) Dipeptidyl Peptidase (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (3) Dopamine Receptor (10) Drug Derivative (1) Drug Isomer (3) Drug-Linker Conjugates for ADC (1) EGFR (12) Endogenous Metabolite (7) Epigenetic Reader Domain (3) ERK (1) FAAH (5) FAK (12) Fatty Acid Synthase (FASN) (2) Ferroptosis (1) FGFR (1) Flavivirus (3) FLT3 (3) Fluorescent Dye (4) Fungal (4) GABA Receptor (2) GCGR (3) GHSR (4) GLP Receptor (1) Glucocorticoid Receptor (3) Glucokinase (4) Glutathione Peroxidase (3) GlyT (2) GSK-3 (2) HCV (3) HDAC (2) Histamine Receptor (5) Histone Acetyltransferase (2) Histone Methyltransferase (3) HIV (4) HSP (3) IFNAR (1) iGluR (4) IKK (3) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (2) Interleukin Related (7) IRAK (2) Isotope-Labeled Compounds (12) Itk (1) JAK (13) Ketohexokinase (1) Kinesin (1) LAG-3 (1) Lipase (1) Liposome (1) Lipoxygenase (1) LPL Receptor (3) LRRK2 (5) mAChR (4) MAGL (1) MAP3K (1) MAP4K (3) MAPKAPK2 (MK2) (1) Melanocortin Receptor (3) Methionine Adenosyltransferase (MAT) (1) mGluR (2) Microsomal Triglyceride Transfer Protein (MTP) (1) Microtubule/Tubulin (4) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (1) Mitosis (1) MMP (3) Monoamine Oxidase (1) Mps1 (2) mTOR (4) nAChR (2) NKCC (3) Opioid Receptor (3) Oxytocin Receptor (6) P2X Receptor (1) p38 MAPK (5) PAK (4) Parasite (28) PARP (10) PCSK9 (6) PD-1/PD-L1 (3) PDHK (1) PDK-1 (1) PGE synthase (2) Phosphatase (1) Phosphodiesterase (PDE) (27) Phospholipase (1) PI3K (6) PI4K (1) PKA (1) PKC (3) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (6) Progesterone Receptor (3) Prostaglandin Receptor (2) PROTACs (3) Protein Arginine Deiminase (3) Proton Pump (1) Pyk2 (5) Pyruvate Kinase (1) Raf (3) Reference Standards (19) RET (2) Ribosomal S6 Kinase (RSK) (1) ROCK (1) ROR (1) ROS Kinase (10) SARS-CoV (7) Ser/Thr Protease (1) SGK (1) SGLT (5) SHP2 (3) Small Interfering RNA (siRNA) (7) Smo (7) Sodium Channel (19) SphK (3) Src (1) STAT (4) TAM Receptor (1) Telomerase (1) TGF-beta/Smad (2) TGF-β Receptor (1) Thrombin (1) Thyroid Hormone Receptor (1) Tissue Factor Pathway Inhibitor (TFPI) (1) TNF Receptor (6) Toll-like Receptor (TLR) (4) Topoisomerase (1) Transmembrane Glycoprotein (1) Trk Receptor (6) TROP2 (1) TRP Channel (4) VEGFR (3) Virus Protease (4) Wnt (1) γ-secretase (5)
By Research Areas:	Cancer (163) Cardiovascular Disease (31) Endocrinology (25) Infection (61) Inflammation/Immunology (98) Metabolic Disease (65) Neurological Disease (109)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) CpG ODNs (2) Mouse Pre-designed siRNA Sets (1) siRNA drugs (2) Human Pre-designed siRNA Sets (3) siRNAs (7)

500

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111371

PF-05180999 PF-999	Phosphodiesterase (PDE)	Neurological Disease
PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC₅₀ of 1.6 nM.

HY-12584

PF-5190457 PF-05190457	GHSR	Metabolic Disease Endocrinology
PF-5190457 (PF-05190457) is a potent and selective ghrelin receptor inverse agonist with a pK_i of 8.36 .

HY-14464

PF-00489791 PF-489791	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
PF-00489791 (PF-489791) is a potent inhibitor of phosphodiesterase 5A with IC₅₀ of 1.5 nM. PF-00489791 can enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function .

HY-117623

PF-06685249 PF-249	AMPK	Metabolic Disease
PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC₅₀ of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 can be used for diabetic nephropathy research .

HY-11028

PF-02413873 PF-2413873	Progesterone Receptor	Endocrinology
PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a K_i of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo .

HY-13007

PF-3758309 5+ Cited Publications PF-03758309	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-120072

PF-3450074 4 Publications Verification PF-74	HIV	Infection
PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC₅₀=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.

HY-13007A

PF-3758309 hydrochloride PF-03758309 hydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-13007B

PF-3758309 dihydrochloride PF-03758309 dihydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-P991371

PF-06478924 PF-06664178 antibody; RN926	TROP2	Cancer
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC₅₀ values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-108691

PF-06465469 2 Publications Verification	Itk Btk CXCR PD-1/PD-L1 LAG-3	Cancer
PF-06465469 is a covalent inhibitor of ITK with an IC₅₀ of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma .

HY-13810

PF-04880594	Raf	Cancer
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .

HY-12883A

PF-05198007	Sodium Channel	Neurological Disease
PF-05198007 is a potent, orally active and selective arylsulfonamide Na_v1.7 inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771 .

HY-117923

PF-06465603	mTOR PI3K	Cancer
PF-06465603 is a highly potent and selective ATP-competitive kinase inhibitor and a class 1 PI3K and mTOR inhibitor. PF-06465603 is a metabolite of PF-04691502 with a terminal carboxylic acid structure .

HY-122805

PF-794	Ser/Thr Protease	Neurological Disease
PF-794 is a potent, selective and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with an IC₅₀ of 39 nM. PF-794 shows selective for the TNIK family. PF-794 reduces endogenous p120-catenin phosphorylation in cells. PF-794 can be used for teh study of psychiatric disorders .

HY-164519

PF-7006	Apoptosis Mps1 Mitosis	Cancer
PF-7006 is an Mps1 kinase inhibitor with a K_i value of 0.27 nM and an IC₅₀ value of 2.5 nM. PF-7006 interferes with cell cycle checkpoints by inhibiting the catalytic activity of Mps1, reducing histone H3 levels, and shortening the duration of mitosis, leading to apoptosis in cancer cells. Combined use of PF-7006 with Palbociclib (HY-50767) increases cancer cell tolerance to PF-7006. PF-7006 can be used for breast cancer research .

HY-19562A

PF-06260933 hydrochloride	MAP4K	Inflammation/Immunology
PF-06260933 hydrochloride is the hydrochloride form of PF-06260933 (HY-19562). PF-06260933 hydrochloride is an orally active and highly selective inhibitor of MAP4K4 with IC₅₀s of 3.7 and 160 nM for kinase and cell, respectively .

HY-10679A

PF-03049423	Phosphodiesterase (PDE)	Neurological Disease
PF-03049423 (Compound PF-5) is a potent and highly selective phosphodiesterase-5A inhibitor with an IC₅₀ of about 0.2 nM for rat and human platelet enzyme. PF-03049423 can be used for the research of acute ischaemic stroke .

HY-120811

PF-04701475	iGluR	Neurological Disease
PF-04701475 is a potent AMPA receptor potentiator with an EC₅₀ of 123 nM. PF-04701475 can be used for the study of neurological disorders .

HY-103682A

PF-06726304 acetate	Histone Methyltransferase	Cancer
PF-06726304 acetate is a potent and selective EZH2 inhibitor. PF-06726304 acetate inhibits wild-type and Y641N mutant EZH2 with K_is of 0.7 and 3.0 nM, respectively. PF-06726304 acetate displays robust antitumor growth activity .

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-103682

PF-06726304 1 Publications Verification	Histone Methyltransferase	Cancer
PF-06726304 is a potent and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with K_is of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity .

HY-12629

PF470 PF-06297470	mGluR	Others
PF470 (PF-06297470) is a negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) with significant efficacy in Parkinson's disease models, but clinical development was halted due to potential issues found in toxicology studies.

HY-116625

PF-04628935	GHSR	Neurological Disease
PF-04628935 (compound 10n) is a potent ghrelin receptor inverse agonist, with an IC₅₀ of 4.6 nM. PF-04628935 exhibits oral bioavailability of 43% in rats and shows reasonable penetration into the brain. PF-04628935 can be used for stress and anxiety research .

HY-138916

PF-06672131	Biochemical Assay Reagents EGFR	Others
PF-06672131 is an alkynylated afatinib derivative and a small molecule probe that is reactive to cysteine. PF-06672131 is an inhibitor of epidermal growth factor receptor (EGFR) kinase that targets the ATP pockets of EGFR. PF-06672131 can be used for activity-based protein profiling studies .

HY-123833

PF-05661014	Sodium Channel	Others
PF-05661014, a desmethyl analogue of PF-06526290, selectively inhibits Nav1.3 and Nav1.7 currents by stabilizing inactivated channels via interaction with D4 VSD. PF-05661014 can be used for research of sodium channel modulation .

HY-19985

PF-06459988	EGFR	Cancer
PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer .

HY-115506

PF-05105679	TRP Channel	Neurological Disease
PF-05105679 is an orally active and selective TRPM8 antagonist with an IC₅₀ of 103 nM. PF-05105679 has the potential for cold-related pain .

HY-100873

PF-1355 2 Publications Verification PF-06281355	Glutathione Peroxidase	Cardiovascular Disease
PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.

HY-139293

PF-07059013	Others	Cardiovascular Disease
PF-07059013 is an orally active and potent noncovalent modulator of sickled hemoglobin (HbS). PF-07059013 specifically binds to Hb with nanomolar affinity and displays strong partitioning into red blood cells (RBCs). PF-07059013 can be used for sickle cell disease (SCD) research .

HY-10032

PF 477736 5 Publications Verification PF 00477736	Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .

HY-19550

PF-06442609	γ-secretase	Neurological Disease
PF-06442609 is an orally active γ secretase modulator, with an IC₅₀ of 6 nM for Aβ42. PF-06442609 possesses brain good penetration .

HY-119103

PF-03246799	5-HT Receptor	Neurological Disease
PF-03246799 (PF-3246799) is a potent and selective 5-HT2C receptor agonist with an EC₅₀ of 190 nM and a K_i of 160 nM. PF-03246799 shows selectivity for 5-HT2C over 5-HT2A and 5-HT2B receptors. PF-03246799 has the potential for stress urinary incontinence (SUI) research .

HY-125789

PF-04753299	Bacterial	Infection
PF-04753299 is a potent and selective UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitor. PF-04753299 is bactericidal for the gonococcal isolates. PF-04753299 inhibits E. coli, P. aeruginosa and K. pneumoniae strains with MIC₉₀ values of 2 μg/ml, 4 μg/ml and 16 μg/ml, respectively. PF-04753299 is used for the study of gram-negative bacteria infection .

HY-124317

PF-06649283	Fluorescent Dye	Others
PF-06649283 is a drug with potential intracellular activity. The effects of PF-06649283 may be affected by factors such as cellular metabolism, protein-protein interactions, post-translational modifications, and asymmetric intracellular localization. The potency of PF-06649283 at the cellular level may show different activity compared to the recombinant enzyme, and this difference needs to be considered in the drug discovery process. Increased intracellular potency of PF-06649283 may be critical for the development of this drug as a probe or drug .

HY-18862

PF-03715455	p38 MAPK	Inflammation/Immunology
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC₅₀ values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC₅₀=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .

HY-19321R

PF-06282999 (Standard)	Glutathione Peroxidase	Cardiovascular Disease
PF-06282999 (Standard) is the analytical standard of PF-06282999. This product is intended for research and analytical applications. PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.

HY-108340

PF-06767832	mAChR	Neurological Disease
PF-06767832 is a potent muscarinic M1 selective positive allosteric modulator (PAM), with the EC₅₀ of 60 nM. PF-06767832 has good brain penetration .

HY-P991407

PF-05230905	TNF Receptor	Inflammation/Immunology
PF-05230905 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. PF-05230905 can be used in Rheumatoid arthritis research .

HY-15691A

PF-4455242 hydrochloride	Opioid Receptor	Inflammation/Immunology
PF-4455242 hydrochloride is a selective, short-acting antagonist of the κ-opioid receptor, exhibiting potential analgesic effects. PF-4455242 hydrochloride has been identified through a strategy utilizing parallel chemistry and physicochemical property design. PF-4455242 hydrochloride demonstrated confirmed potency and selectivity in the tail-flick analgesia model.

HY-120103

PF-06649298 1 Publications Verification	Sodium Channel	Metabolic Disease
PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC₅₀ value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .

HY-18138

PF-03382792	5-HT Receptor	Neurological Disease
PF-03382792 is a potent 5-HT₄ partial agonist with a K_i of 2.7 nM and an EC₅₀ of 0.9 nM for 5-HT_4d. PF-03382792 can penetrate the brain. PF-03382792 produces moderate increases in cortical Ach in the rat prefrontal cortex .

HY-11044

PF-03654746 Tosylate	Histamine Receptor	Neurological Disease Inflammation/Immunology Endocrinology
PF-03654746 Tosylate is a potent and selective histamine H3 receptor antagonist with high brain penetration. PF-03654746 Tosylate reduces allergen-induced nasal symptoms . PF-03654746 Tosylate has potential for treatment of human cognitive disorders, improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD) .

HY-120789

PF-06648671	γ-secretase	Neurological Disease
PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease .

HY-170443

PF-07265028	MAP4K	Cancer
PF-07265028 is a selective hematopoietic progenitor kinase 1 (HPK1/MAP4K1). PF-07265028 can be used in the research of cancer. PF-07265028 shows very potent cellular activity as measured by pSLP76 IC₅₀ (17 nM) .

HY-14250

PF-998425	Androgen Receptor	Endocrinology
PF-998425 is a potent, selective nonsteroidal androgen receptor (AR) antagonist with an IC₅₀ of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .

HY-10461R

PF-573228 (Standard)	Reference Standards FAK Apoptosis	Cancer
PF-573228 (Standard) is the analytical standard of PF-573228. This product is intended for research and analytical applications. PF-573228 is a potent and selective FAK inhibitor with IC50 of 4 nM for purified recombinant catalytic fragment of FAK.

HY-117048

PF-4191834 PF-04191834	Lipoxygenase	Inflammation/Immunology
PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the 5-Lipoxygenase (5-LOX) (IC₅₀=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective in inflammation and pain .

HY-101024

PF-06263276	JAK STAT	Inflammation/Immunology
PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC₅₀s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276 inhibits pSTAT3 and TYK2 pathway. PF-06263276 has a protective effect against ear skin inflammation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-156193

PF-07208254	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	PDHK
PF-07208254 is a selective, orally active allosteric inhibitor of branched-chain ketoacid dehydrogenase kinase (BDK) (IC₅₀=110 nM, K_i=54 nM, K_D=84 nM). PF-07208254 inhibits BDK-mediated BCKDH phosphorylation and enhances the catabolism of branched-chain amino acids (BCAAs) and branched-chain keto acids (BCKAs) by binding to the allosteric pocket of BDK, reducing BDK binding to BCKDH-E2 and promoting BDK degradation. PF-07208254 inhibits BDK activity in human skeletal muscle cells (IC₅₀=540 nM) and has activity to improve cardiac function and metabolism. PF-07208254 can be used in the study of cardiometabolic diseases (e.g., heart failure, type 2 diabetes) .

HY-12361

PF 1022A 1 Publications Verification	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Parasite
PF 1022A is a cyclooctadepsipeptide with broadspectrum anthelmintic properties produced by fermentation of the fungus Mycelia sterilia. PF 1022A is a channel-forming ionophore. PF 1022A showes strong anthelmintic activities against *Ascaridia galli* in chickens. PF 1022A also can be used for angiostrongyliasis research .

HY-155156

PF-07238025	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-167884

PF-1367550	Structural Classification Alkaloids Aristolochia debilis Sieb. et Zucc. Source classification Plants Aristolochiaceae	JAK
PF-1367550 is a pan-JAK inhibitor. PF-1367550 can decrease the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells .

HY-123474

PF-1163B	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Fungal Antibiotic
PF-1163B is an antifungal antibiotic .

HY-12361R

PF 1022A (Standard)	Structural Classification Natural Products Microorganisms Source classification	Reference Standards Parasite
PF 1022A (Standard) is the analytical standard of PF 1022A. This product is intended for research and analytical applications. PF 1022A is a cyclooctadepsipeptide with broadspectrum anthelmintic properties produced by fermentation of the fungus Mycelia sterilia. PF 1022A is a channel-forming ionophore. PF 1022A showes strong anthelmintic activities against Ascaridia galli in chickens. PF 1022A also can be used for angiostrongyliasis research[1][2][3].

HY-120333

Antibiotic PF 1052	Infection Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Source classification Disease Research Disease Research Fields Other Antibiotics	Antibiotic Fungal Bacterial
Antibiotic PF 1052 is an antibiotic extracted from a natural product library. Antibiotic PF 1052 has an inhibitory effect on murine neutrophil migration .

HY-N15072

Naphthomycinol	Structural Classification Microorganisms Macrolide Antibiotics Antibiotics Source classification	Others
Naphthomycinol is a neuroprotective agent found in Str. sp. PF7 .

HY-N14945

Diazaphilonic acid	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Telomerase
Diazaphilonic acid is found in the strain of Talaramuces flavus PF1195. Diazaphilonic acid has no antibacterial activity, but inhibits the ability of DNA amplification and telomerase .

HY-Y1309

1-Naphthol Furro ER; NSC 9586; Nako TRB	Structural Classification Monophenols Classification of Application Fields Source classification Other Diseases Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
1-naphthol (Furro ER) is an excited state proton transfer (ESPT) fluorescent molecular probe. 1-naphthol can sense the hydrophobic domains in micellar aggregation and accurately sense the sol-gel transition. 1-naphthol can be used to study the thermally induced microenvironmental changes and hydration levels of Pluronic F127 (PF127) in different microenvironments in aqueous media .

Cat. No.	Product Name	Chemical Structure

HY-138687S

Nirmatrelvir-d9
Nirmatrelvir-d9 (PF-07321332-d9) is the deuterium labeled Nirmatrelvir (HY-138687) .

HY-12522S

PF-06380101-d8 2 Publications Verification
PF-06380101-d₈ is a deuterium labeled PF-06380101. PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue .

HY-16391S1

Glasdegib-d4
Glasdegib-d₄ (PF-04449913-d₄) is deuterium labeled Glasdegib. Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC₅₀ of 4 nM .

HY-138687S1

Nirmatrelvir-d6
Nirmatrelvir-d₆ (PF-07321332-d₆) is deuterium labeled Nirmatrelvir. Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL ^PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-13272S3

Dacomitinib-d10
Dacomitinib-d₁₀ is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .

HY-13272S2

Dacomitinib-d10 dihydrochloride
Dacomitinib-d₁₀ dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .

HY-50878S2

Crizotinib-d9

Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878S1

Crizotinib-d8

Crizotinib-d₈ (PF-02341066-d₈) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-15461S

Ertugliflozin-d5
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin . Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461S1

Ertugliflozin-d9
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-12289S

Defactinib-d6
Defactinib-d6 is a deuterium labeled Defactinib (HY-12289). Defactinib is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities .

HY-10617AS

Rucaparib-d8
Rucaparib-d₈ (AG014699-d₈ ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10978S

Crisaborole-d4
Crisaborole-d₄ is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.

HY-10392S

Sutezolid-13C4
Sutezolid- ¹³C₄ (PNU-100480- ¹³C₄) is ¹³C labeled Sutezolid. Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks